Navigation Links
Soligenix to Present at the 2014 Biotech Showcase in San Francisco
Date:1/9/2014

PRINCETON, N.J., Jan. 9, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 2014 Biotech Showcase in San Francisco, California on Tuesday, January 14, 2014 at 11:00 AM Pacific Standard Time (PST).  The presentation will take place on the third floor of the Parc 55 Wyndham Hotel. 

The Soligenix presentation will be webcast live and archived for later replay. To access the webcast, please visit the company's investor page at http://www.soligenix.com/invest_sec.shtml.  A replay of the presentation will be archived after the conference at the same location.

For more information about the 2014 Biotech Showcase, please refer to the conference website at www.ebdgroup.com/bts/index.php.

About Soligenix, Inc.

Soligenix is a clinical stage biopharmaceutical company developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics. Soligenix is developing proprietary formulations of oral BDP (beclomethasone 17,21-dipropionate) for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn's disease (SGX203), acute radiation enteritis (SGX201) and chronic Graft-versus-Host disease (orBec®), as well as developing its novel innate defense regulator (IDR) technology SGX942 for the treatment of oral mucositis.  

Through its BioDefense Division, Soligenix is developing countermeasures pursuant to the Biomedical Advanced Research and Development Authority (BARDA) Strategic Plan of 2011-2016 for inclusion in the US government's Strategic National Stockpile. Soligenix's biodefense products in development are a recombinant subunit vaccine called RiVax™, which is designed to protect against the lethal effects of exposure to ricin toxin and VeloThrax™, a vaccine against anthrax exposure. RiVax™ has been shown to be well tolerated and immunogenic in two Phase 1 clinical trials in healthy volunteers. Both RiVax™ and VeloThrax™ are currently the subject of a $9.4 million National Institute of Allergy and Infectious Diseases (NIAID) grant supporting development of Soligenix's new vaccine heat stabilization technology known as ThermoVax™.  Soligenix is also developing OrbeShield™ for the treatment of gastrointestinal acute radiation syndrome (GI ARS) under a BARDA contract award valued up to $26.3 million and a NIAID contract award valued up to $6.4 million. OrbeShield™ has previously demonstrated statistically significant preclinical survival results in a canine model of GI ARS funded by the NIAID.  Additionally, Soligenix has an exclusive worldwide collaboration with Intrexon Corporation focused on the joint development of a treatment for Melioidosis, a high priority biothreat and an area of unmet medical need.

For further information regarding Soligenix, Inc., please visit the Company's website at www.soligenix.com.

This press release contains forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations and clinical trial enrollment.  Statements that are not historical facts, such as "anticipates," "estimates," "believes," "intends," "potential," or similar expressions, are forward-looking statements.  These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements.  Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats conducting preclinical and clinical trials of vaccines, obtaining regulatory approvals and manufacturing vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the US Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program.  These and other risk factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K.  Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.


'/>"/>
SOURCE Soligenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Soligenix Announces Initiation of a Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
2. Soligenix Reports Third Quarter 2013 Financial Results, and Highlights Recent Accomplishments
3. Soligenix Submits NIAID Contract Proposal for Development of a Thermostable Ricin Vaccine
4. Soligenix Announces Appointment of Marco Maria Brughera to its Board of Directors
5. Soligenix to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
6. Soligenix Reports Second Quarter 2013 Financial Results, and Highlights Recent Accomplishments
7. Soligenix Announces Pricing of Public Offering of Common Stock and Warrants
8. FDA Grants Soligenix "Fast Track" Designation for SGX942 for the Treatment of Oral Mucositis in Patients with Head and Neck Cancer
9. Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohns Disease
10. Soligenix Reports First Quarter 2013 Financial Results and Highlights Recent Accomplishments
11. Soligenix and Intrexon Pursue Melioidosis Therapy Through Worldwide Exclusive Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2017)... July 31, 2017 7D Surgical, developer of ground ... purchased the 7D Surgical System to support its strategic sales ... D.C. and Virginia.  7D Surgical has entered into ... of the premier medical facilities within those markets. ... ...
(Date:7/28/2017)... --EnvoyHealth, a Diplomat company, has partnered with Compliance Meds ... a technology designed to improve patient medication adherence. ... solutions and services that help track and improve patients, ... LITE offers medication monitoring and control for patients and ... Records date and time of bottle ...
(Date:7/27/2017)... Pa., July 27, 2017  West Pharmaceutical Services, Inc. ... results for the second-quarter 2017 and updated financial guidance ... Second-Quarter 2017 Highlights Reported net ... over the prior-year quarter. Net sales at constant currency ... reported-diluted EPS was $0.51, compared to $0.60 in the ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... ... Pastor and Overseer at The House of Yahweh in Abilene, Texas, has released a new ... the mother of the Savior whom the world calls “Mother Mary”. Yisrayl says when compared ... of this historical woman. , “The world bows, kisses the feet of, cries out ...
(Date:8/18/2017)... CARMEL, IN (PRWEB) , ... August 18, 2017 , ... ... 36th annual list, the most prestigious ranking of the nation's fastest-growing private companies. This ... in the exclusive Inc. 5000 ranking . This year’s ranking reflects ASH’s 76 ...
(Date:8/18/2017)... ... 18, 2017 , ... “Our Mountains to Climb: A Journey of Love and ... stronger together through the faith they shared to overcome struggles in life. “Our Mountains ... published author, Barbara J. Corcoran, a retired teacher and happily married since 1999; the ...
(Date:8/18/2017)... ... ... “Three Narrow Roads”: a vivid and provocative look into the narrow path toward ... Sr., is currently the pastor-teacher-visionary at Simply the WORD Church, a global prayer ministry ... program geared towards youth. , King shares, “When I take time to think about ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Depressed: Super Heroes of the Bible”: ... reflect upon the stories and the relevance these tales may have on the reader’s ... Linhart, a former special education teacher, Jessica spends much of her time enjoying nature ...
Breaking Medicine News(10 mins):